Studies on the metabolism of 4-methyl-piperazine-1-carbodithioc acid 3-cyano-3,3-diphenylpropyl ester hydrochloride in rats by high-performance liquid chromatography/electro spray ionization tandem mass spectrometry

Department of Pharmaceutical Analysis, School of Pharmaceutical Sciences, Peking University, Xueyuan Road 38, Beijing 100083, China.
Journal of Pharmaceutical and Biomedical Analysis (Impact Factor: 2.98). 10/2007; 44(5):1127-32. DOI: 10.1016/j.jpba.2007.05.026
Source: PubMed


4-Methyl-piperazine-1-carbodithioc acid 3-cyano-3,3-diphenylpropyl ester hydrochloride(TM208) is a newly synthesized compound, which has shown excellent in vivo and in vitro anticancer activity and low toxicity. In this study, the metabolism of TM208 in rats was studied for the first time by high-performance liquid chromatography coupled with tandem mass spectrometry. Following a single oral administration to rats, TM208 was metabolized to eight metabolites (M1-M8). M1 is the desmethyl metabolite and the acylation of M1 with N-acetyl transferase results in M6 (N-acetyl metabolite), M5 is N-formyl metabolite; M4 is phenyl monohydroxylation metabolite, M2 is the sulfine metabolite of TM208, and M3 is also an odd-oxygen added products which the possible oxidation site has described in this paper; M8 is the metabolite resulting from the replacement of '-C=S' with '-C=O', M7 is a ring-opened piperazine oxidation products to a kind of acid.

65 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: A new, specific and sensitive high performance liquid chromatography analytical procedure was developed and validated for the determination of TM208 in rat primary solid organs/tissues and plasma. TM208 was extracted from the appropriate matrix using methanol followed by centrifugation at 11,255×g for 20min and injection of a 30μL aliquot. Separation was carried out under gradient conditions using an ODS C18 column equipped with a guard column. The mobile phase consisted of methanol and water and retention times of TM208 and plunarizine (IS) were 17.658 and 26.175min, respectively. The analytical procedure provided acceptable precision, accuracy, recoveries and linearity. Stability studies showed that TM208 was stable in organs/tissues homogenates for three freeze–thaw cycles, at room temperature for at least 24h 3weeks at −20°C. The validated method was successfully applied to the determination of TM208 in SD rats following oral administration at a dose of 250mgkg−1.
    Chromatographia 12/2009; 70(11):1721-1725. DOI:10.1365/s10337-009-1402-7 · 1.41 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: 4-Methylpiperazine-1-carbodithioic acid 3-cyano-3,3-diphenylpropyl ester hydrochloride (TM208) is a new compound expected to become a new drug because of excellent in vivo and in vitro anticancer activity and low toxicity. A new, specific and sensitive LC method was set up for detecting the bioavailability of TM208 after oral administration. Samples were extracted with ethyl acetate after oral and intravenous administration. The retention times of TM208 and plunarizine (I.S.) were 5.5 and 9.9 min, respectively. The linear range was 0.125–50 μg mL−1. The accuracy (error, %) for three concentrations was 2.7–16.6%. Intra-day precision (as RSD) was 1.6–6.9% and inter-day precision was 7.6–11.5%. Extraction recovery of TM208 was 84.15–89.51% and that of the I.S. was 83.3%. Results from stability testing indicated that samples should be analyzed within 24 h or frozen immediately for later analysis. The bioavailable fraction (F) calculated by use of a non-compartment model was 63.3%. Pharmacokinetic data for TM208 were: mean residence time 24.3 and 5.1 h, V d 186.2 and 35.5 L kg−1, and Cl 6.9 and 4.2 L h−1 kg−1 after oral and intravenous administration, respectively. LC–MS comparison of the metabolites after the two methods of administration showed the kind and content of metabolites of TM208 in rat urine after intravenous administration were more than after oral administration. The experimental results show that the low anticancer activity of TM208 after intravenous administration is related to rapid elimination of the drug, and that the kind and content of metabolites do not affect the bioactivity of TM208.
    Chromatographia 09/2010; 72(5):459-464. DOI:10.1365/s10337-010-1697-4 · 1.41 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A method for the simultaneous determination of TM208 and its major metabolite (sulfine 4-methyl-piperazine-1-carbodithioc acid 3-cyano-3,3-diphenylpropyl ester, TM208-SO) was developed and validated for the first time. The analytes were extracted from plasma samples by liquid-liquid extraction and analyzed using high-performance liquid chromatography. Flunarizine hydrochloride was used as the internal standard. Chromatographic separations were performed on a Diamonsil C(18) analytical column. The mobile phases consisted of 20 mM ammonium acetate adjusted to pH 4.20 with acetic acid (solvent A) and acetonitrile (solvent B). The analytes were detected at 254 nm after linear gradient elution. The flow rate was 0.8 mL/min. Linearity was obtained over the concentration range of 0.104-5.20 microg/mL for TM208 and 0.145-5.80 microg/mL for TM208-SO in rat plasma. The limit of quantification was 0.104 microg/mL for TM208 and 0.145 microg/mL for TM208-SO, respectively. The inter- and intra-day precision was less than 12.8% for TM208 and 14.1% for TM208-SO. And the accuracy was 96.2-111.1% for TM208 and 95.5-108.6% for TM208-SO. This analytic procedure was applied to a pharmacokinetic study of TM208 and TM208-SO in rats, and the pharmacokinetic parameters were calculated.
    Journal of chromatographic science 02/2010; 48(2):125-9. DOI:10.1093/chromsci/48.2.125 · 1.36 Impact Factor
Show more